Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment-Reference-Cited by-同舟云学术

Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment

Published:2023-01-19 Issue:3 Volume:41 Page:295-306
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Lu Yuqiong,Dai Zhanjing,Chang Feng,Wang Li,He Jiafang,Shi Penghua,Zhang Haitao,Lu Yun

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-022-01232-9.pdf

Reference62 articles.

1. Crivellaro S, Sofer L, Halgrimson WR, Dobbs RW, Serafini P. Optimized clinical decision-making: a configurable Markov model for benign prostatic hyperplasia treatment. Urology. 2019;132:183–8. https://doi.org/10.1016/j.urology.2019.06.022.

2. Disutility [online] (2016) York: York Health Economics Consortium; 2016. Available at: https://yhec.co.uk/glossary/disutility/. Accessed 2 Mar 2022.

3. Guan H, Liu G, Xie F, Sheng Y, Shi L. Cost-effectiveness of osimertinib as a second-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer in China. Clin Ther. 2019;41(11):2308-2320.e11. https://doi.org/10.1016/j.clinthera.2019.09.008.

4. Davies EW, Llewellyn S, Beaudet A, Kosmas CE, Gin-Sing W, Doll HA. Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension. Patient Prefer Adherence. 2018;12:1079–88. https://doi.org/10.2147/PPA.S160662.

5. McEwan P, Baker-Knight J, Ásbjörnsdóttir B, Yi Y, Fox A, Wyn R. Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China. Eur J Health Econ. 2022. https://doi.org/10.1007/s10198-022-01470-w. (Epub 8 May 2022).

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

2. Methods for Including Adverse Events in Economic Evaluations: Suggestions for Improvement;Value in Health;2024-07

3. The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China;Frontiers in Public Health;2024-04-15

4. Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review;Targeted Oncology;2024-03-11

5. Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy;Advances in Therapy;2024-02-08